SV40 large T Antigen (T) forms complexes with the product of the retinoblastoma gene (RB), a known tumor and growth suppressor. Complex formation is essential for full T transforming function. Underlying this is evidence showing that, upon binding, T down modulates one or more aspects of the growth suppression function of RB. RB growth suppression function is, at least in part, a product of specific interactions with a group of cellular proteins which bind to an internal RB protein receptor domain called the 'pocket.' One of these proteins is the transcription factor, E2F, a growth promoting element responsible for activating a number of genes whose products are essential for exit from G0/G1 and passage through S. Unphosphorylated RB, T releases E2F from the RB pocket, enhancing its activity and simultaneously promoting passage of a G1-arrested cell into S. This proposal is aimed at better understanding how RB operates biochemically and, in particular, at gaining new insights into the nature of the full RB tumor suppression function. In particular, the work will attempt to understand the significance of RB interactions with a newly cloned RB binding protein, RBAP-2. It will search for evidence that RB functions after it is phosphorylated. It will attempt to learn whether RB has transformation suppression functions beyond its ability to stop growth in G1. An effort to probe the potential role of the N-terminal 378 aa of RB will be initiated, since this region is suspected of contributing to RB functions other than G1 growth suppression. Finally, the significance of a recently detected interaction between RB and the oncogene product, mdm2, a known suppressor of p53 growth regulatory function will be pursued. The ultimate goal of the work is to understand how the T-RB interaction contributes to SV40 tumorigenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA050661-08
Application #
5207605
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
1996
Total Cost
Indirect Cost
Becker, Jürgen C; Stang, Andreas; Hausen, Axel Zur et al. (2018) Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer Immunol Immunother 67:341-351
Becker, Jürgen C; Stang, Andreas; DeCaprio, James A et al. (2017) Merkel cell carcinoma. Nat Rev Dis Primers 3:17077
Denis, Deborah; Rouleau, Cecile; Schaffhausen, Brian S (2017) A Transformation-Defective Polyomavirus Middle T Antigen with a Novel Defect in PI3 Kinase Signaling. J Virol 91:
Starrett, Gabriel J; Marcelus, Christina; Cantalupo, Paul G et al. (2017) Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma. MBio 8:
Cizmecioglu, Onur; Ni, Jing; Xie, Shaozhen et al. (2016) Rac1-mediated membrane raft localization of PI3K/p110? is required for its activation by GPCRs or PTEN loss. Elife 5:
Rouleau, Cecile; Pores Fernando, Arun T; Hwang, Justin H et al. (2016) Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP. J Virol 90:7032-7045
Berrios, Christian; Jung, Joonil; Primi, Blake et al. (2015) Malawi polyomavirus is a prevalent human virus that interacts with known tumor suppressors. J Virol 89:857-62
Luo, Leo Y; Kim, Eejung; Cheung, Hiu Wing et al. (2015) The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Mol Cancer Res 13:502-9
Hettmer, Simone; Schinzel, Anna C; Tchessalova, Daria et al. (2015) Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. Elife 4:
White, Elizabeth A; Kramer, Rebecca E; Hwang, Justin H et al. (2015) Papillomavirus E7 oncoproteins share functions with polyomavirus small T antigens. J Virol 89:2857-65

Showing the most recent 10 out of 147 publications